Family medicine clinicians need to understand maintenance strategies because weight regain is the primary clinical challenge after GLP-1 discontinuation, with patients typically recovering 50-70% of lost weight within one year. Lilly’s data on continued GLP-1 use or dose optimization for weight maintenance directly impacts counseling conversations about realistic long-term treatment expectations and helps inform individualized decisions regarding duration of therapy versus chronic management. Maintenance data also influence cost-benefit discussions with patients and insurance formularies, as evidence supporting extended or maintenance dosing affects both clinical outcomes and access to therapy in primary care practice.

Eli Lilly presented data evaluating maintenance of weight loss achieved with GLP-1 receptor agonists, focusing on strategies to sustain therapeutic benefit in patients who have responded to treatment. The data examined approaches for preventing weight regain in patients treated with Lilly’s GLP-1 formulations, addressing a clinically relevant question regarding the durability of weight loss once patients reach their treatment goals or discontinue active dose escalation.

Key findings indicate that patients who have achieved weight loss on GLP-1 therapy can maintain the majority of their weight reduction through continuation strategies. This suggests that ongoing treatment with these agents preserves the metabolic and behavioral modifications that contribute to initial weight loss, distinguishing this class from earlier weight loss interventions where rapid weight regain was common upon discontinuation. The data support a model in which GLP-1 therapy functions as a maintenance treatment rather than a short-term intervention, with sustained dosing preventing the typical weight rebound observed when pharmacologic support is withdrawn.

For prescribers, these findings have practical implications for long-term management planning. Patients who achieve meaningful weight loss on GLP-1 therapy and wish to maintain results should be counseled that continued treatment is necessary, as the medication addresses underlying physiologic drivers of obesity rather than providing temporary suppression of appetite. This supports the clinical approach of treating obesity with GLP-1 agents as a chronic disease requiring sustained pharmacotherapy, similar to management strategies employed for hypertension or diabetes, rather than as a time-limited intervention.

GLP-1 medications demonstrate sustained weight loss maintenance when continued long-term, with Eli Lilly’s data supporting ongoing therapy rather than discontinuation after initial weight loss. Patients who maintain GLP-1 treatment retain approximately 80-90% of achieved weight loss, compared to significant regain in those who stop therapy. This evidence reinforces that GLP-1s function as chronic disease management tools similar to diabetes or hypertension medications, requiring indefinite continuation for sustained benefit. In clinical practice, frame GLP-1 therapy as long-term management from the outset, setting realistic expectations that stopping medication typically results in weight regain and helping patients understand this reflects the chronic nature of obesity rather than personal failure.

“What Lilly’s maintenance data really tells us is that we need to reframe how patients think about GLP-1 therapy from the start. These agents work best as a long-term tool, not a sprint to a finish line, which means I’m now explicitly counseling patients at initiation that discontinuation typically results in weight regain unless they’ve made substantial lifestyle modifications that can sustain the loss independently. The clinical implication is straightforward: we should be using the GLP-1 window to build durable behavioral changes, not just chase numbers on the scale. This data reinforces what we’re seeing in practice-these medications are most effective when patients view them as ongoing metabolic support rather than a temporary intervention.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: